Arcellx Gives Company Highlights and Stories 2nd Quarter 2022 Economical Effects

— Finished upsized follow-on supplying of typical inventory, raising $128.8 million in gross proceeds like comprehensive training of underwriters’ selection to acquire extra shares —

— Offered continued sturdy lengthy-term responses from its CART-ddBCMA Stage 1 growth demo being evaluated in clients with r/r MM at the 2022 ASCO Once-a-year Conference —

— Preclinical benefits from CART-ddBCMA published in Molecular Cancer Therapeutics —

REDWOOD City, Calif., Aug. 15, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology enterprise reimagining mobile remedy by means of the improvement of impressive immunotherapies for people with most cancers and other incurable disorders, currently reported company highlights and fiscal success for the next quarter ended June 30, 2022.

“We are enthusiastic about the speedy progress we have produced given that turning out to be a general public enterprise in February of this year,” reported Rami Elghandour, Arcellx’s Chairman and Chief Govt Officer. “In the second quarter, we realized significant milestones with the presentation of new clinical facts for our direct merchandise prospect, CART-ddBCMA, during an oral presentation at ASCO strengthened our balance sheet with a effective adhere to-on featuring, elevating gross proceeds of $128.8 million dosed our initially affected individual in ACLX-001, our Section 1 study utilizing our Arc-SparX engineering and expanded our management crew and Board of Directors with remarkable specialists including to the range of our workforce. In the next half of this yr, we search ahead to presenting an encore presentation of our CART-ddBCMA Phase 1 study at ESMO, initiating our Phase 2 pivotal CART-ddBCMA (iMMagine) trial in clients with relapsed or refractory various myeloma (r/r MM), presenting longer-time period affected individual data from our Section 1 CART-ddBCMA growth demo in r/r MM, and initiating our Stage 1 ARC-SparX clinical trial of ACLX-002 in people with acute myeloid leukemia and high-threat myelodysplastic syndrome. We are fully commited to establishing Arcellx as a top mobile therapy organization by continuing to scale our organization, advancing our novel platform to help as many sufferers as achievable, and attracting…